Updated consensus statement on biological agents, specifically tumour necrosis factor α (TNFα) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2004
Open Access
- 1 November 2004
- journal article
- review article
- Published by Elsevier in Annals of the Rheumatic Diseases
- Vol. 63 (suppl 2) , ii2-ii12
- https://doi.org/10.1136/ard.2004.029272
Abstract
The perspective of this consensus is from the treating physician’s point of view.Keywords
This publication has 123 references indexed in Scilit:
- Safety of Tumour Necrosis Factor-?? AntagonistsDrug Safety, 2004
- How to RECOVER from RENAISSANCE? The significance of the results of RECOVER, RENAISSANCE, RENEWAL and ATTACHInternational Journal of Cardiology, 2002
- Combination of steroids with infliximab or placebo in severe alcoholic hepatitis: a randomized controlled pilot studyJournal of Hepatology, 2002
- Etanercept versus methotrexate in patients with early rheumatoid arthritis: Two‐year radiographic and clinical outcomesArthritis & Rheumatism, 2002
- Maintenance infliximab for Crohn's disease: the ACCENT I randomised trialPublished by Elsevier ,2002
- Remission of Behçet's syndrome with TNFα blocking treatmentAnnals of the Rheumatic Diseases, 2002
- Tuberculosis Associated with Infliximab, a Tumor Necrosis Factor α–Neutralizing AgentNew England Journal of Medicine, 2001
- InfliximabDrugs, 2000
- EtanerceptDrugs, 1999
- Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor αArthritis & Rheumatism, 1993